Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib

Sridevi Challa; W. Lee Kraus

doi:10.1016/j.chembiol.2022.02.002

Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib

Sridevi Challa, W. Lee Kraus

Research output: Contribution to journal › Comment/debate › peer-review

3 Scopus citations

Abstract

In this issue of Cell Chemical Biology, Palve et al. (2022) identified PARP16 as a non-canonical therapeutic target of the PARP1 inhibitor talazoparib, which synergizes with the WEE1 inhibitor adavosertib to enhance its efficacy. The dual targeting of PARP1 and PARP16 may explain the greater efficacy of talazoparib in some cancers.

Original language	English (US)
Pages (from-to)	171-173
Number of pages	3
Journal	Cell Chemical Biology
Volume	29
Issue number	2
DOIs	https://doi.org/10.1016/j.chembiol.2022.02.002
State	Published - Feb 17 2022

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Molecular Biology
Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.1016/j.chembiol.2022.02.002

Cite this

@article{ccbd2ad969fd4d7fb1306a811967b37c,

title = "Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib",

abstract = "In this issue of Cell Chemical Biology, Palve et al. (2022) identified PARP16 as a non-canonical therapeutic target of the PARP1 inhibitor talazoparib, which synergizes with the WEE1 inhibitor adavosertib to enhance its efficacy. The dual targeting of PARP1 and PARP16 may explain the greater efficacy of talazoparib in some cancers.",

author = "Sridevi Challa and Kraus, {W. Lee}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = feb,

day = "17",

doi = "10.1016/j.chembiol.2022.02.002",

language = "English (US)",

volume = "29",

pages = "171--173",

journal = "Cell Chemical Biology",

issn = "2451-9456",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Two birds, one stone

T2 - Non-canonical therapeutic effects of the PARP inhibitor Talazoparib

AU - Challa, Sridevi

AU - Kraus, W. Lee

PY - 2022/2/17

Y1 - 2022/2/17

N2 - In this issue of Cell Chemical Biology, Palve et al. (2022) identified PARP16 as a non-canonical therapeutic target of the PARP1 inhibitor talazoparib, which synergizes with the WEE1 inhibitor adavosertib to enhance its efficacy. The dual targeting of PARP1 and PARP16 may explain the greater efficacy of talazoparib in some cancers.

AB - In this issue of Cell Chemical Biology, Palve et al. (2022) identified PARP16 as a non-canonical therapeutic target of the PARP1 inhibitor talazoparib, which synergizes with the WEE1 inhibitor adavosertib to enhance its efficacy. The dual targeting of PARP1 and PARP16 may explain the greater efficacy of talazoparib in some cancers.

UR - http://www.scopus.com/inward/record.url?scp=85124548584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124548584&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2022.02.002

DO - 10.1016/j.chembiol.2022.02.002

M3 - Comment/debate

C2 - 35180430

AN - SCOPUS:85124548584

SN - 2451-9456

VL - 29

SP - 171

EP - 173

JO - Cell Chemical Biology

JF - Cell Chemical Biology

IS - 2

ER -

Two birds, one stone: Non-canonical therapeutic effects of the PARP inhibitor Talazoparib

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this